MARKET

PSYBF

PSYBF

Psybio Therapeau
OTCMQB
0.053
+0.017
+48.33%
Closed 12:45 12/02 EST
OPEN
0.053
PREV CLOSE
0.036
HIGH
0.053
LOW
0.053
VOLUME
500
TURNOVER
27
52 WEEK HIGH
0.790
52 WEEK LOW
0.036
MARKET CAP
2.65M
P/E (TTM)
-0.8116
1D
5D
1M
3M
1Y
5Y
BRIEF-Psybio Therapeutics Announces Non-Brokered Private Placement Financing
Reuters · 3d ago
PsyBio Therapeutics Reports Third Quarter 2022 Financial Results
OXFORD, Ohio and DENVER, Nov. 29, 2022 /CNW/ – PsyBio Therapeutics Corp. (TSXV: PSYB) (OTCQB: PSYBF) ("PsyBio" or the "Company"), a fully integrated and intellectual property driven biotechnology company developing novel psychoactive medicinal candidates t...
CNW Group · 5d ago
Yeast Produces Bread And Psilocybin, This Company Is Moving Into Clinical Trial Phase
The current clinical scenario sets psilocybin as one of the most advanced psychedelics, expected to become legally approved in the US sometime between the 2023-2024 period and to become available as of Januar
Benzinga · 10/11 18:30
BRIEF-Psybio Therapeutics Reaches Agreement To Conduct Initial Psilocybin Clinical Trial
BRIEF-Psybio Therapeutics Reaches Agreement To Conduct Initial Psilocybin Clinical Trial
Reuters · 10/11 11:42
PsyBio Therapeutics Latest U.S. PCT (Non-Provisional) Patent Application Accepted
PsyBio Therapeutics Corp. (TSXV: PSYB) (OTCQB: PSYBF) ("PsyBio" or the "Company"), an intellectual property driven biotechnology company focused upon discovery and development of novel, bespoke, psycho-targeted therapeutics to potentially improve mental an...
CNW Group · 09/19 11:30
PsyBio Therapeutics to Present at Upcoming Investor Events in September 2022
PsyBio Therapeutics Corp. (TSXV: PSYB) (OTCQB: PSYBF) ("PsyBio" or the "Company"), a fully integrated and intellectual property driven biotechnology company developing novel psychoactive medicinal candidates targeting the potential treatment of mental heal...
CNW Group · 09/07 11:30
Most, But Not All, Psychedelics Companies Have Sufficient Liquidity
The Chart represents the liquidity positions of the 21 Psychedelic sector companies in the Viridian Value Tracker database.
Benzinga · 09/06 15:25
DMT Producer PsyBio And Shrooms Grower Red Light Holland Share Their Most Recent Financial Results
PsyBio Therapeutics (TSXV: PSYB) (OTCQB: PSYBF), a biotech developing medicines based on naturally-occurring psychedelic substances, announced the release of its financial results for the three and six month period ended June 30, 2022 along with recent corporate news.
Benzinga · 08/29 20:09
More
About PSYBF
Psybio Therapeutics Corp, formerly Leo Acquisitions Corp, is a Canada-based biotechnology company developing a new class of drugs intended for the treatment of mental health challenges and other disorders. The Company is developing a portfolio of psychoactive compounds targeted for the treatment of mental health challenges and other disorders. The Company is engaged in the process of developing new drugs by producing psychoactive molecules from genetically modified bacteria.

Webull offers kinds of Psybio Therapeutics Corp stock information, including OTCMQB:PSYBF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PSYBF stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PSYBF stock methods without spending real money on the virtual paper trading platform.